CA3026512C - Composes modulant le fxr (nr1h4) - Google Patents

Composes modulant le fxr (nr1h4)

Info

Publication number
CA3026512C
CA3026512C CA3026512A CA3026512A CA3026512C CA 3026512 C CA3026512 C CA 3026512C CA 3026512 A CA3026512 A CA 3026512A CA 3026512 A CA3026512 A CA 3026512A CA 3026512 C CA3026512 C CA 3026512C
Authority
CA
Canada
Prior art keywords
liver
fxr
compound
alkyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3026512A
Other languages
English (en)
Other versions
CA3026512A1 (fr
Inventor
Peter A. Blomgren
Kevin S. Currie
Julie Farand
Christian Gege
Jeffrey E. Kropf
Jianjun Xu
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Priority claimed from PCT/US2017/036743 external-priority patent/WO2017218337A1/fr
Publication of CA3026512A1 publication Critical patent/CA3026512A1/fr
Application granted granted Critical
Publication of CA3026512C publication Critical patent/CA3026512C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

Il est essentiellement décrit des composés représentés par la formule (I) [voir la figure I] dans laquelle Z est : (voir la figure II), lesdits composés se liant au récepteur de l’élément 4 du groupe H de la sous-famille 1 du récepteur nucléaire farnésoïde X et agissant en tant qu’agonistes du récepteur farnésoïde X. Il est également décrit l’utilisation des composés pour la préparation d’un médicament pour le traitement de maladies et/ou des conditions au moyen de liaison dudit récepteur nucléaire par lesdits composés, ainsi qu’un procédé de la synthèse desdits composés.
CA3026512A 2016-06-13 2017-06-09 Composes modulant le fxr (nr1h4) Active CA3026512C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662349479P 2016-06-13 2016-06-13
US62/349,479 2016-06-13
PCT/US2017/036743 WO2017218337A1 (fr) 2016-06-13 2017-06-09 Composés modulant le fxr (nr1h4)

Publications (2)

Publication Number Publication Date
CA3026512A1 CA3026512A1 (fr) 2017-12-21
CA3026512C true CA3026512C (fr) 2025-12-09

Family

ID=

Similar Documents

Publication Publication Date Title
US12358903B2 (en) FXR (NR1H4) modulating compounds
AU2021254625B2 (en) FXR (NR1H4) modulating compounds
EP3468977B1 (fr) Nouveaux composés modulant le fxr (nr1h4)
HK40029408A (en) Azetidine derivatives as fxr (nr1h4) modulators
HK40029408B (en) Azetidine derivatives as fxr (nr1h4) modulators
HK40084541A (en) Fxr (nr1h4) modulating compounds
HK40119080A (en) Fxr (nr1h4) modulating compounds
HK40006547B (en) Fxr (nr1h4) modulating compounds
HK1247924B (en) Fxr (nr1h4) modulating compounds
NZ789188A (en) FXR (NR1H4) modulating compounds
HK1262117B (en) Fxr (nr1h4) modulating compounds
HK1262117A1 (en) Fxr (nr1h4) modulating compounds